DOCSLIB.ORG

Ocular Oncology and Pathology 2018 Hot Topics in Ocular Pathology and Oncology— an Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ocular Oncology and Pathology 2018 Hot Topics in Ocular Pathology and Oncology— an Update Ocular Oncology and Pathology 2018 Hot Topics in Ocular Pathology and Oncology— An Update Program Directors Patricia Chévez-Barrios MD and Dan S Gombos MD In conjunction with the American Association of Ophthalmic Oncologists and Pathologists McCormick Place Chicago, Illinois Saturday, Oct. 27, 2018 Presented by: The American Academy of Ophthalmology 2018 Ocular Oncology and Pathology Subspecialty Day Advisory Committee Staff Planning Group Daniel S Durrie MD Melanie R Rafaty CMP DES, Director, Patricia Chévez-Barrios MD Associate Secretary Scientific Meetings Program Director Julia A Haller MD Ann L’Estrange, Subspecialty Day Manager Dan S Gombos MD Michael S Lee MD Carolyn Little, Presenter Coordinator Program Director Francis S Mah MD Debra Rosencrance CMP CAE, Vice R Michael Siatkowski MD President, Meetings & Exhibits Former Program Directors Kuldev Singh MD MPH Patricia Heinicke Jr, Copy Editor 2016 Carol L Shields MD Mark Ong, Designer Maria M Aaron MD Gina Comaduran, Cover Designer Patricia Chévez-Barrios MD Secretary for Annual Meeting 2014 Hans E Grossniklaus MD Arun D Singh MD ©2018 American Academy of Ophthalmology. All rights reserved. No portion may be reproduced without express written consent of the American Academy of Ophthalmology. ii Planning Group 2018 Subspecialty Day | Ocular Oncology & Pathology 2018 Ocular Oncology and Pathology Planning Group On behalf of the American Academy of Ophthalmology and the American Association of Ophthalmic Oncologists and Pathologists, it is our pleasure to welcome you to Chicago and Ocular Oncology and Pathology 2018: Hot Topics in Ocular Pathology and Oncology—An Update. Patricia Chévez-Barrios MD Dan S Gombos MD Program Director Program Director NASA: S Aura: C | Castle: C Children’s Oncology Group : S Iconic Therapeutics: C Lois Kuss Fund for Glaucoma Research: S The Houseman/Wilkins Ophthalmological Foundation: S 2018 Subspecialty Day | Ocular Oncology & Pathology Planning Group iii 2018 Subspecialty Francis S Mah MD Kuldev Singh MD MPH (Cornea) (Glaucoma) Day Advisory Abbott Medical Optics Aerie: C Inc.: C,L,S Alcon Laboratories Inc.: C Committee Aerie: C | Alcon: C Allergan: C Allergan: C Belkin Laser Ltd.: C Daniel S Durrie MD, Chair Avedro, Inc.: C Glaukos Corp.: C (Refractive Surgery) Avellino Labs: C InjectSense: C | Ivantis: C AcuFocus Inc.: C,L,O Bausch Lomb: C,L Johnson & Johnson: C Alcon Laboratories Inc.: S CoDa: C | EyePoint: C Mynosys: C Alphaeon: C,O inVirsa: C | iView: C National Eye Institute: S Avedro: C,L,O KALA: C Novartis Institute for Biomedical Concierge Key Health: C,O Mallinckrodt Pharmaceuticals: C Research: C Eyedetec Medical Inc.: C NovaBay: C Ocular Therapeutix Inc.: C Eyegate Pharma: C Novartis, Alcon Pharmaceuticals: Santen Inc.: C | Shire: C Hoopes Durrie Rivera Research C,L Thieme Medical Publishers: C Center: C Ocular Science: C,O U.S. Food and Drug Johnson & Johnson Vision: C,L Ocular Therapeutix: C,S Administration: C,S Strathspey Crown LLC: C,O Okogen: C,O Omeros Corporation: C Julia A Haller MD PolyActiva: C (Retina) AAO Staff RxSight: C Aura Biosciences: C Senju: S | Shire: C,L Celgene: O | KalVista: C Ann L’Estrange Slack Publishing: C,P Lowy Medical Research None Sun Pharma: C,L Institute: C Sydnexis: C,O Novartis Pharmaceuticals Carolyn Little TearLab: C Corp.: C None Spark Therapeutics: C R Michael Siatkowski MD Melanie Rafaty Michael S Lee MD (Pediatric Ophthalmology) None National Eye Institute: S (Neuro-Ophthalmology) National Eye Institute: S Debra Rosencrance Quark Pharmaceuticals: S None Springer: P Uptodate: P Beth Wilson None 2018 Subspecialty Day | Ocular Oncology & Pathology Contents v Ocular Oncology and Pathology 2018 Contents Program Planning Group ii CME vi Faculty Listing viii How to Use the Audience Interaction Application xiii Program Schedule xiv Section I: Oncologist and Pathologist Hand in Hand 1 Section II: Pro and Con Debate and Roundtable on Retinoblastoma 16 Advocating for the Profession and Patients 21 Section III: Hot Topics in Retinoblastoma 21 Section IV: Uveal Melanoma—Hot and Spicy Topics 39 Section V: Uveal Melanoma—Pro and Con Debate 48 Section VI: Multicenter Trials in Ocular Oncology—2018 Update 52 Section VII: Gender Research in Ocular Tumors 61 Section VIII: Clinical Wisdom From Our Senior Leadership 66 Faculty Financial Disclosure 69 Presenter Index 72 vi CME 2018 Subspecialty Day | Ocular Oncology & Pathology CME Credit Academy’s CME Mission Statement Scientific Integrity and Disclosure of Conflicts of Interest The purpose of the American Academy of Ophthalmology’s Continuing Medical Education (CME) program is to present The American Academy of Ophthalmology is committed to ophthalmologists with the highest quality lifelong learning ensuring that all CME information is based on the application opportunities that promote improvement in physician practices, of research findings and the implementation of evidence-based resulting in the best possible eye care for their patients. medicine. It seeks to promote balance, objectivity, and absence of commercial bias in its content. All persons in a position to control the content of this activity must disclose any and all 2018 Ocular Oncology and Pathology Subspecialty financial interests. The Academy has mechanisms in place to Day Learning Objectives resolve all conflicts of interest prior to an educational activity Upon completion of this activity, participants should be able to: being delivered to the learners. The Academy requires all presenters to disclose on their first ■ Identify clinical and pathologic features of certain slide whether they have any financial interests from the past 12 tumors, such as ocular melanoma, retinoblastoma, and months. Presenters are required to verbally disclose any finan- conjunctival premalignant lesions cial interests that specifically pertain to their presentation. ■ Identify and manage treatment complications such as sec- ond tumors and metastasis ■ Recognize advances in liquid biopsies and ocular pathol- Control of Content ogy The American Academy of Ophthalmology considers present- ■ Determine when a patient should be referred to an ing authors, not coauthors, to be in control of the educational ocular oncology center and when to consult an ocular content. It is Academy policy and traditional scientific publish- pathologist ing and professional courtesy to acknowledge all people con- tributing to the research, regardless of CME control of the live 2018 Ocular Oncology and Pathology Subspecialty presentation of that content. This acknowledgment is made in a Day Target Audience similar way in other Academy CME activities. Though they are acknowledged, coauthors do not have control of the CME con- The intended audience for this program is ocular oncology and tent, and their disclosures are not published or resolved. pathology surgeons, comprehensive ophthalmologists with an interest in anterior segment, and allied health personnel who are performing or assisting with ocular oncology and pathology Attendance Verification for CME Reporting surgery. Before processing your requests for CME credit, the American Academy of Ophthalmology must verify your attendance at 2018 Ocular Oncology and Pathology Subspecialty Subspecialty Day and/or AAO 2018. In order to be verified for Day CME Credit CME or auditing purposes, you must either: The American Academy of Ophthalmology is accredited by ■ Register in advance, receive materials in the mail, and the Accreditation Council for Continuing Medical Education turn in the Subspecialty Day Syllabi exchange voucher(s) (ACCME) to provide CME for physicians. onsite; The Academy designates this live activity for a maximum ■ Register in advance and pick up your badge onsite if of 7 AMA PRA Category 1 Credits™. Physicians should claim materials did not arrive before you traveled to the meet- only the credit commensurate with the extent of their participa- ing; tion in the activity. ■ Register onsite; or ■ Scan the barcode on your badge as you enter an AAO 2018 course or session room. Teaching at a Live Activity Teaching instruction courses or delivering a scientific paper or CME Credit Reporting poster is not an AMA PRA Category 1 Credit™ activity and should not be included when calculating your total AMA PRA South Building Level 2.5 and Academy Resource Center Category 1 Credits™. Presenters may claim AMA PRA Cat- Attendees whose attendance has been verified (see above) at egory 1 Credits™ through the American Medical Association. AAO 2018 can claim their CME credit online during the meet- To obtain an application form please contact the AMA at ing. Registrants will receive an email during the meeting with www.ama-assn.org. the link and instructions on how to claim credit. Onsite, you may report credits earned during Subspecialty Day and/or AAO 2018 at the CME Credit Reporting booth. 2018 Subspecialty Day | Ocular Oncology & Pathology CME vii Academy Members Proof of Attendance The CME credit reporting receipt is not a CME transcript. The following types of attendance verification are available dur- CME transcripts that include AAO 2018 credits entered at the ing AAO 2018 and Subspecialty Day for those who need it for Academy’s annual meeting will be available to Academy mem- reimbursement or hospital privileges, or for nonmembers who bers through the Academy’s CME web page (www.aao.org/ need it to report CME credit: cme-central) beginning Thursday, Dec. 13. The Academy transcript cannot list individual course atten- ■ CME credit reporting/proof-of-attendance letters dance.
Load more

Recommended publications
  • Optic Nerve Invasion of Uveal Melanoma: Clinical Characteristics and Metastatic Pattern
    Optic Nerve Invasion of Uveal Melanoma: Clinical Characteristics and Metastatic Pattern Jens Lindegaard,1,2 Peter Isager,3,4 Jan Ulrik Prause,1,2 and Steffen Heegaard1 PURPOSE. To determine the frequency of optic nerve invasion in present independently of decreased visual acuity and tumor uveal melanoma, to identify clinical factors associated with location. (Invest Ophthalmol Vis Sci. 2006;47:3268–3275) optic nerve invasion, and to analyze the metastatic pattern and DOI:10.1167/iovs.05-1435 the association with survival. METHODS. All iris, ciliary body, and choroidal melanomas (N ϭ veal melanoma is the most frequent primary intraocular 2758) examined between 1942 and 2001 at the Eye Pathology Umalignant tumor in adults; in Scandinavia, the incidence 1–4 Institute, University of Copenhagen, Denmark, and the Insti- rate is 5.3 to 8.7 per million person-years. The tumor has a tute of Pathology, Aarhus University Hospital, Aarhus, Den- great propensity to metastasize and to affect the liver in par- 3,5,6 mark, were reviewed. Cases with optic nerve invasion were ticular. Local spread occurs through the overlying Bruch identified and subdivided into prelaminar or laminar invasion membrane, giving access to the subretinal space, or toward the and postlaminar invasion. Clinical characteristics were com- orbit (through the sclera, most often along ciliary vessels and pared with those from 85 cases randomly drawn from all ciliary nerves). Uveal melanoma infiltrates the optic nerve in only body and choroidal melanomas without optic nerve invasion 0.6% to 5% of patients and has been associated with high intraocular pressure, non–spindle cell type, juxtapapillary lo- from the same period.
    [Show full text]
  • Retinoblastoma Major Review with Updates on Middle East Management Protocols
    Saudi Journal of Ophthalmology (2012) 26, 163–175 Ophthalmic Pathology Update Retinoblastoma major review with updates on Middle East management protocols ⇑ Ihab Saad Othman, MD, FRCS Abstract Many advances in the field of management of retinoblastoma emerged in the past few years. Patterns of presentation of retino- blastoma in the Middle East region differ from Western community. The use of enucleation as a radical method of eradicating advanced disease is not easily accepted by patient’s family. We still do see stage E, failed or resistant retinoblastoma and advanced extraocular disease ensues as a result of delayed enucleation decision. In this review, we discuss updates in management of retinoblastoma with its implication on patients in our part of the world. Identifying clinical and high risk characteristics is impor- tant prognostically and are discussed for further management of retinoblastoma cases. Keywords: Retinoblastoma, Staging, Classification, Histopathology, Middle East Ó 2012 Saudi Ophthalmological Society, King Saud University. All rights reserved. http://dx.doi.org/10.1016/j.sjopt.2012.03.002 Introduction cases is 100–120 cases/year.3 In a recent report from Jordan, the mean age-adjusted incidence of retinoblastoma was 9.32 Retinoblastoma is the commonest primary ocular malig- cases per million children per year for children aged 0– nancy of childhood originating from primitive retinoblasts 5 years.4 Retinoblastoma constituted 4.8% of childhood can- with tendency towards cone differentiation. Retinoblasts cer treated over 10 years at the National Cancer Institute in arise from the inner neuroepithelial layers of the embryonic Sudan and presented in an advanced stage in 16 out of 25 re- optic cup.1 The incidence of retinoblastoma ranges from 1/ ported cases.5 15,000 to 1/20,000 live births with an annual incidence in chil- dren younger than 5 years of 10.9/million.
    [Show full text]
  • Glaucoma Related to Ocular and Orbital Tumors Sonal P
    Chapter Glaucoma Related to Ocular and Orbital Tumors Sonal P. Yadav Abstract Secondary glaucoma due to ocular and orbital tumors can be a diagnostic challenge. It is an essential differential to consider in eyes with a known tumor as well as with unilateral, atypical, asymmetrical, or refractory glaucoma. Various intraocular neoplasms including iris and ciliary body tumors (melanoma, metasta- sis, lymphoma), choroidal tumors (melanoma, metastasis), vitreo-retinal tumors (retinoblastoma, medulloepithelioma, vitreoretinal lymphoma) and orbital tumors (extra-scleral extension of choroidal melanoma or retinoblastoma, primary orbital tumors) etc. can lead to raised intraocular pressure. The mechanisms for glaucoma include direct (tumor invasion or infiltration related outflow obstruction, tra- becular meshwork seeding) or indirect (angle closure from neovascularization or anterior displacement or compression of iris) or elevated episcleral venous pressure secondary to orbital tumors. These forms of glaucoma need unique diagnostic techniques and customized treatment considerations as they often pose therapeutic dilemmas. This chapter will review and discuss the mechanisms, clinical presenta- tions and management of glaucoma related to ocular and orbital tumors. Keywords: ocular tumors, secondary glaucoma, orbital tumors, angle infiltration, neovascular glaucoma, neoplastic glaucoma 1. Introduction With the advent of constantly evolving and advancing ophthalmic imaging tech- niques as well as surgical modalities in the field of ophthalmic diseases, diagnostic accuracy, and treatment outcomes of ocular as well as orbital tumors have improved remarkably over the past few years. Raised intraocular pressure (IOP) is known to be one of the presenting features or associated finding for numerous ocular as well as orbital tumors. Ocular and orbital tumors can cause secondary glaucoma due to various mechanisms.
    [Show full text]
  • Commentary on the Masquerades of A
    perim Ex en l & ta a l ic O p in l h t C h f Journal of Clinical & Experimental a o l m l a o n l r o Chua, J Clin Exp Ophthalmol 2016, 7:2 g u y o J Ophthalmology 10.4172/2155-9570.1000543 ISSN: 2155-9570 DOI: Commentary Open Access Commentary on the Masquerades of a Childhood Ciliary Body Medulloepithelioma: A Case of Chronic Uveitis, Cataract, and Secondary Glaucoma Jocelyn Chua* Eye Specialist Clinic, 290 Orchard Road, Singapore *Corresponding author: Dr Jocelyn Chua, Eye Specialist Clinic, 290 Orchard Road, #06-01 to 05, 238859, Singapore; Tel: +65 96897919; Email: [email protected], [email protected] Received date: February 09, 2016; Accepted date: April 20, 2016; Published date: April 25, 2016 Copyright: © 2016 Chua J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Commentary Ciliary body medulloepithelioma is the commonest ciliary body tumor in childhood. The term “medulloepithelioma”, coined by "The masquerades of a childhood ciliary body medulloepithelioma: Grinker in 1931, best describes the origin of the tumor from the A case of chronic uveitis, cataract and secondary glaucoma" by Chua et primitive medullary epithelium located along the inner layer of the al. [1] is a case report of a healthy two year old boy who presented with optic cup. This undifferentiated medullary epithelium forms the non- a unilateral cataract, anterior uveitis and glaucoma after an innocuous pigmented ciliary body epithelium in the later years of development.
    [Show full text]
  • Small Choroidal Melanoma with All Eight Risk Factors for Growth
    RETINAL ONCOLOGY CASE REPORTS IN OCULAR ONCOLOGY SECTION EDITOR: CAROL L. SHIELDS, MD Small Choroidal Melanoma With All Eight Risk Factors for Growth BY FELINA V. ZOLOTAREV, BA; KIRAN TURAKA, MD; AND CAROL L. SHIELDS, MD veal melanoma prognosis is A B C dependent on several factors including tumor size, location, U configuration, extraocular extension, cell type, and cytogenetic abnormalities. In general, the smaller the tumor, the better the prognosis.1 In a recent publication on 8,033 eyes with DE uveal melanoma, it was documented that increasing thickness of uveal melanoma was associated with greater risk for metastasis and ultimate death.1 Patients with uveal melanoma measuring 2.5 mm Figure 1. Features of small choroidal melanoma. A pigmented choroidal tumor thickness showed metastasis in 12% at 10 superior to the macula displays orange pigment, seen on autofluorescence (A, years as compared with 26% for those at B), hollowness on ultrasonography (C), and subretinal fluid, depicted on opti- 4.5 mm thickness.1 Hence, early detection cal coherence tomography (D, E). Note the lack of drusen or halo.These fea- of uveal melanoma is important. tures are most consistent with melanoma. The dilemma of early recognition cen- ters on the difficulty in differentiating a benign melanoma display two or three of these factors.2 In this choroidal nevus from a small malignant melanoma. Risk case presentation, we describe a small melanoma with factors for identification of small melanoma, when it all eight risk factors and discuss the importance of early might resemble choroidal nevus, have been identified detection of uveal melanoma.
    [Show full text]
  • Uveal Melanoma-Derived Extracellular Vesicles Display Transforming Potential and Carry Protein Cargo Involved in Metastatic Niche Preparation
    cancers Article Uveal Melanoma-Derived Extracellular Vesicles Display Transforming Potential and Carry Protein Cargo Involved in Metastatic Niche Preparation Thupten Tsering 1, Alexander Laskaris 1, Mohamed Abdouh 1 , Prisca Bustamante 1 , Sabrina Parent 1 , Eva Jin 1, Sarah Tadhg Ferrier 1, Goffredo Arena 1,2,3 and Julia V. Burnier 1,4,* 1 Cancer Research Program, Research Institute of the McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada; [email protected] (T.T.); [email protected] (A.L.); [email protected] (M.A.); [email protected] (P.B.); [email protected] (S.P.); [email protected] (E.J.); [email protected] (S.T.F.); goff[email protected] (G.A.) 2 Ospedale Giuseppe Giglio Fondazione San Raffaele Cefalu Sicily, 90015 Cefalu, Italy 3 Mediterranean Institute of Oncology, 95029 Viagrande, Italy 4 Experimental Pathology Unit, Department of Pathology, McGill University, QC H3A 2B4, Canada * Correspondence: [email protected]; Tel.: +1-514-934-1934 (ext. 76307) Received: 13 September 2020; Accepted: 7 October 2020; Published: 11 October 2020 Simple Summary: Uveal melanoma is a rare but deadly cancer that shows remarkable metastatic tropism to the liver. Extracellular vesicles (EVs) are nanometer-sized, lipid bilayer-membraned particles that are released from cells. In our study we used EVs derived from primary normal choroidal melanocytes and matched primary and metastatic uveal melanoma cell lines from a patient. Analysis of these EVs revealed important protein signatures that may be involved in tumorigenesis and metastatic dissemination. We have established a model to study EV functions and phenotypes which can be used in EV-based liquid biopsy.
    [Show full text]
  • (Diktyoma) Presenting As a Perforated, Infected Eye
    Br J Ophthalmol: first published as 10.1136/bjo.61.3.229 on 1 March 1977. Downloaded from British Journal of Ophthalmology, 1977, 61, 229-232 Medulloepithelioma (diktyoma) presenting as a perforated, infected eye MOHAMED A. VIRJI Central Pathology Laboratory, Ministry of Health, Dar-es-Salaam, Tanzania SUMMARY A case of embryonal medulloepithelioma (diktyoma) presenting with perforated infected eye in a 13-year-old Black African girl is described. The tumour mass occupied most of the deformed eye, and invasion of the sclera anteriorly was seen. There was no evidence of orbital or distant tumour involvement. It is suggested that with increasing age these tumours are more likely to show frankly malignant features. Medulloepithelioma (diktyoma) is a rare neoplasm anteriorly perforated left eye, with loss of cornea, of the eye which is characterised by slow growth and purulent discharge, and a fragmenting mass of local invasion and is composed of glandular, irregular brownish-grey tissue attached mainly to neural, and mesenchymal elements (Andersen, the superior and temporal portion of the eye and 1962). It presents even rarely as an infected perfor- extending into the posterior chamber. The infection ated eye with a fungating mass replacing the ocular was controlled with systemic antibiotics and the left copyright. contents. Soudakoff (1936) reported the case of a eye was enucleated. Radiological examination of 28-year-old Chinese who had a perforated eye with the skull showed no orbital involvement, and chest tumour mass completely filling it. This paper x-rays were normal. Postoperative recovery was reports the case of a young black African girl who uneventful.
    [Show full text]
  • Melanomas Are Comprised of Multiple Biologically Distinct Categories
    Melanomas are comprised of multiple biologically distinct categories, which differ in cell of origin, age of onset, clinical and histologic presentation, pattern of metastasis, ethnic distribution, causative role of UV radiation, predisposing germ line alterations, mutational processes, and patterns of somatic mutations. Neoplasms are initiated by gain of function mutations in one of several primary oncogenes, typically leading to benign melanocytic nevi with characteristic histologic features. The progression of nevi is restrained by multiple tumor suppressive mechanisms. Secondary genetic alterations override these barriers and promote intermediate or overtly malignant tumors along distinct progression trajectories. The current knowledge about pathogenesis, clinical, histological and genetic features of primary melanocytic neoplasms is reviewed and integrated into a taxonomic framework. THE MOLECULAR PATHOLOGY OF MELANOMA: AN INTEGRATED TAXONOMY OF MELANOCYTIC NEOPLASIA Boris C. Bastian Corresponding Author: Boris C. Bastian, M.D. Ph.D. Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology Departments of Dermatology and Pathology University of California, San Francisco UCSF Cardiovascular Research Institute 555 Mission Bay Blvd South Box 3118, Room 252K San Francisco, CA 94158-9001 [email protected] Key words: Genetics Pathogenesis Classification Mutation Nevi Table of Contents Molecular pathogenesis of melanocytic neoplasia .................................................... 1 Classification of melanocytic neoplasms
    [Show full text]
  • Retinoblastoma Simulators
    Retinoblastoma: Atypical Presentation & Simulators Dr. Njambi Ombaba; Paediatric Ophthalmologist, University of Nairobi Objectives • To review of typical presentation of retinoblastoma • To understand the atypical presentation • To understand the Rb simulators Presentation of retinoblastoma Growth patterns Endophytic: Inner retina, vitreous mass, no overlying vessels, pseudohypopyon Exophytic: Outer retina, SR space mass, overlying vessels, RD Diffuse: No mass, signs of inflammation/ endophthalmitis Echogenic soft tissue mass Variable shadowing – calcification Persistent on reduced gain Heterogeneous – necrosis/ haemorrhage Floating debris- vitreous seeds, increased globulin MRI- • Pre-treatment staging T1- Hyper intense to vitreous T2-Hypo intense to vitreous T1:C+Gd- homo/ heterogeneous Enhancement: Choroid & AC ON involvement Hypo intense sclera- Normal Trilateral retinoblastoma CT SCAN Typically a mass of high density Usually calcified and moderately enhancing on iodinated contrast CT has a sensitivity of 81–96%, and a higher specificity for calcification detection However, delineation of intraocular soft-tissue detail is limited. Low sensitivity for ON invasion Atypical presentation Non calcified Retinoblastoma Calcification is key to diagnosis retinoblastoma US detects calcifications in 92–95% of positive cases Non-calcified retinoblastomas: 1. Tumefaction with irregular internal structure 2. Medium reflectivity 3. Typical signs of vascularity 4. Retinal detachment with part of the retinal surface destroyed. Rare, 2% of all
    [Show full text]
  • ICO Residency Curriculum 2Nd Edition and Updated Community Eye Health Section
    ICO Residency Curriculum 2nd Edition and Updated Community Eye Health Section The International Council of Ophthalmology (ICO) Residency Curriculum offers an international consensus on what residents in ophthalmology should be taught. While the ICO curriculum provides a standardized content outline for ophthalmic training, it has been designed to be revised and modified, with the precise local detail for implementation left to the region’s educators. Download the Curriculum from the ICO website: icoph.org/curricula.html. www.icoph.org Copyright © International Council of Ophthalmology 2016. Adapt and translate this document for your noncommercial needs, but please include ICO credit. All rights reserved. First edition 201 6 . First edition 2006, second edition 2012, Community Eye Health Section updated 2016. International Council of Ophthalmology Residency Curriculum Introduction “Teaching the Teachers” The International Council of Ophthalmology (ICO) is committed to leading efforts to improve ophthalmic education to meet the growing need for eye care worldwide. To enhance educational programs and ensure best practices are available, the ICO focuses on "Teaching the Teachers," and offers curricula, conferences, courses, and resources to those involved in ophthalmic education. By providing ophthalmic educators with the tools to become better teachers, we will have better-trained ophthalmologists and professionals throughout the world, with the ultimate result being better patient care. Launched in 2012, the ICO’s Center for Ophthalmic Educators, educators.icoph.org, offers a broad array of educational tools, resources, and guidelines for teachers of residents, medical students, subspecialty fellows, practicing ophthalmologists, and allied eye care personnel. The Center enables resources to be sorted by intended audience and guides ophthalmology teachers in the construction of web-based courses, development and use of assessment tools, and applying evidence-based strategies for enhancing adult learning.
    [Show full text]
  • Successful Treatment of Ciliary Body Medulloepithelioma with Intraocular
    Stathopoulos et al. BMC Ophthalmology (2020) 20:239 https://doi.org/10.1186/s12886-020-01512-y CASE REPORT Open Access Successful treatment of ciliary body medulloepithelioma with intraocular melphalan chemotherapy: a case report Christina Stathopoulos*, Marie-Claire Gaillard, Julie Schneider and Francis L. Munier Abstract Background: Intraocular medulloepithelioma is commonly treated with primary enucleation. Conservative treatment options include brachytherapy, local resection and/or cryotherapy in selected cases. We report for the first time the use of targeted chemotherapy to treat a ciliary body medulloepithelioma with aqueous and vitreous seeding. Case presentation: A 17-month-old boy with a diagnosis of ciliary body medulloepithelioma with concomitant seeding and neovascular glaucoma in the right eye was seen for a second opinion after parental refusal of enucleation. Examination under anesthesia showed multiple free-floating cysts in the pupillary area associated with iris neovascularization and a subluxated and notched lens. Ultrasound biomicroscopy revealed a partially cystic mass adjacent to the ciliary body between the 5 and 9 o’clock meridians as well as multiple nodules in the posterior chamber invading the anterior vitreous inferiorly. Fluorescein angiography demonstrated peripheral retinal ischemia. Left eye was unremarkable. Diagnosis of intraocular medulloepithelioma with no extraocular invasion was confirmed and conservative treatment initiated with combined intracameral and intravitreal melphalan injections given according to the previously described safety-enhanced technique. Ciliary tumor and seeding totally regressed after a total of 3 combined intracameral (total dose 8.1 μg) and intravitreal (total dose 70 μg) melphalan injections given every 7–10 days. Ischemic retina was treated with cryoablation as necessary.
    [Show full text]
  • Download Report Appendixes [PDF · 224
    Appendices Appendix A. Selected Internet Links Appendix Table A1. Internet links for radiotherapy organizations Organization URL address Deutsche Gesellschaft fur http://www.degro.org/jsp_public/cms/index.jsp Radiooncologie European Society for Therapeutic http://www.estroweb.org/estro/index.cfm Radiology and Oncology American Society for Therapeutic http://www.astro.org/ Radiology and Oncology National Association for Proton http://www.proton-therapy.org/ Therapy Particle Therapy Cooperative http://ptcog.web.psi.ch/ Group (Accessed June 16, 2008) Appendix Table A2. Internet links for particle beam instrumentation companies Company URL address Ion Beam Applications (IBA) http://www.iba-worldwide.com/ Solutions Still River Systems Inc http://www.stillriversystems.com/ Optivus Proton Therapy http://www.optivus.com/ Siemens http://www.medical.siemens.com/ Hitachi: Proton beam Therapy http://www.pi.hitachi.co.jp/rd-eng/product/industrial-sys/accelerator- sys/proton-therapy-sys/proton-beam-therapy/index.html ACCEL Instruments http://www.proton-therapy.com/ (Accessed June 16, 2008) Appendix Table A3. Internet links for particle beam treatment centers in the USA Center/Institute URL address Francis H. Burr Proton Therapy http://www.massgeneral.org/cancer/about/providers/radiation/proton/i Center (NPTC) ndex.asp Loma Linda University Proton http://www.llu.edu/proton/index.html Therapy Center University of California, Crocker http://media.cnl.ucdavis.edu/crocker/website/default.php Nuclear Lab Midwest Proton Radiotherapy http://www.mpri.org/ Institute, Bloomington M.D. Anderson Proton Therapy http://www.mdanderson.org/care_centers/radiationonco/ptc/ Center, Houston University of Florida Proton http://www.floridaproton.org/ Therapy Institute, Jacksonville (Accessed June 16, 2008) A-1 Appendix B.
    [Show full text]